We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...
Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...
WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...
Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...
WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...
Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and ...
Wegen der andauernden gesundheitlichen Schwäche von Papst Franziskus wird in Rom weiter über mögliche Nachfolger spekuliert. Nun hat ein Verein von Missbrauchsbetroffenen sechs Kardinäle angezeigt, ...
To help you manage symptoms of AS, a doctor may recommend a therapy called biologics. AS primarily affects the spinal joints, but large joints, such as the hips and shoulders, can also be involved.
Welche Prognosen gibt es vor diesem Hintergrund für die weitere Rentenentwicklung in Deutschland? Wie genau hat sich die Durchschnittsrente überhaupt bis heute entwickelt und wie steht ...
Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...
The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...